Laura K Hummers

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi Recurrent transverse myelitis associates with anti-Ro (SSA) autoantibodies
    L K Hummers
    Department of Medicine, Johns Hopkins University, Baltimore, MD 21224, USA
    Neurology 62:147-9. 2004
  2. ncbi Biomarkers of vascular disease in scleroderma
    L K Hummers
    Johns Hopkins Scleroderma Center, Johns Hopkins University, Baltimore, MD 21224, USA
    Rheumatology (Oxford) 47:v21-2. 2008
  3. ncbi The current state of biomarkers in systemic sclerosis
    Laura K Hummers
    Division of Rheumatology, Johns Hopkins Scleroderma Center, Johns Hopkins University, 5501 Hopkins Bayview Circle, Baltimore, MD 21224, USA
    Curr Rheumatol Rep 12:34-9. 2010
  4. ncbi Abnormalities in the regulators of angiogenesis in patients with scleroderma
    Laura K Hummers
    Department of Medicine, Johns Hopkins University, Baltimore, MD 21224, USA
    J Rheumatol 36:576-82. 2009
  5. ncbi Microvascular damage in systemic sclerosis: detection and monitoring with biomarkers
    Laura K Hummers
    Johns Hopkins SSc Center, Baltimore, MD 21224, USA
    Curr Rheumatol Rep 8:131-7. 2006
  6. ncbi Tricuspid annular plane systolic excursion is a robust outcome measure in systemic sclerosis-associated pulmonary arterial hypertension
    Stephen C Mathai
    Divisions of Pulmonary and Critical Care Medicine, Cardiology, and Rheumatology, Department of Medicine, Johns Hopkins, University School of Medicine, Baltimore, Maryland, USA
    J Rheumatol 38:2410-8. 2011
  7. ncbi Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension
    Aránzazu Campo
    MD, Division of Pulmonary and Critical Care Medicine, 1830 E Monument St, Fifth Floor, Baltimore, MD 21205, USA
    Am J Respir Crit Care Med 182:252-60. 2010
  8. ncbi Late-age onset systemic sclerosis
    Rebecca L Manno
    Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
    J Rheumatol 38:1317-25. 2011
  9. ncbi Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease
    Stephen C Mathai
    Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Arthritis Rheum 60:569-77. 2009
  10. ncbi Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies
    Jerome Le Pavec
    Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Arthritis Rheum 63:2456-64. 2011

Research Grants

  1. Biomarkers of Vascular Disease in Scleroderma
    Laura Hummers; Fiscal Year: 2007

Collaborators

Detail Information

Publications26

  1. ncbi Recurrent transverse myelitis associates with anti-Ro (SSA) autoantibodies
    L K Hummers
    Department of Medicine, Johns Hopkins University, Baltimore, MD 21224, USA
    Neurology 62:147-9. 2004
    ..Antibodies to 52-kd Ro were demonstrated in 77% of cases (10/13) compared with only 33% of control subjects (4/12)...
  2. ncbi Biomarkers of vascular disease in scleroderma
    L K Hummers
    Johns Hopkins Scleroderma Center, Johns Hopkins University, Baltimore, MD 21224, USA
    Rheumatology (Oxford) 47:v21-2. 2008
    ..In this review, we will critically assess our current knowledge of the use of biomarkers of vascular disease in scleroderma and the possible directions of future research in this area...
  3. ncbi The current state of biomarkers in systemic sclerosis
    Laura K Hummers
    Division of Rheumatology, Johns Hopkins Scleroderma Center, Johns Hopkins University, 5501 Hopkins Bayview Circle, Baltimore, MD 21224, USA
    Curr Rheumatol Rep 12:34-9. 2010
    ..This review examines the current state of biomarker development in systemic sclerosis and identifies areas in which further work should be directed...
  4. ncbi Abnormalities in the regulators of angiogenesis in patients with scleroderma
    Laura K Hummers
    Department of Medicine, Johns Hopkins University, Baltimore, MD 21224, USA
    J Rheumatol 36:576-82. 2009
    ..To determine plasma levels of regulators of angiogenesis in patients with scleroderma and to correlate those levels with manifestations of scleroderma-related vascular disease...
  5. ncbi Microvascular damage in systemic sclerosis: detection and monitoring with biomarkers
    Laura K Hummers
    Johns Hopkins SSc Center, Baltimore, MD 21224, USA
    Curr Rheumatol Rep 8:131-7. 2006
    ..This paper examines the possibility of using circulating biomarkers to assess vascular disease activity and to predict severe vascular events among patients with SSc...
  6. ncbi Tricuspid annular plane systolic excursion is a robust outcome measure in systemic sclerosis-associated pulmonary arterial hypertension
    Stephen C Mathai
    Divisions of Pulmonary and Critical Care Medicine, Cardiology, and Rheumatology, Department of Medicine, Johns Hopkins, University School of Medicine, Baltimore, Maryland, USA
    J Rheumatol 38:2410-8. 2011
    ..But its role in systemic sclerosis (SSc)-associated PAH has not been established. Our objective was to validate the TAPSE in the assessment of RV function and prediction of survival in SSc-PAH...
  7. ncbi Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension
    Aránzazu Campo
    MD, Division of Pulmonary and Critical Care Medicine, 1830 E Monument St, Fifth Floor, Baltimore, MD 21205, USA
    Am J Respir Crit Care Med 182:252-60. 2010
    ..Objectives: To identify risk factors of mortality in a well-characterized cohort of patients with PAH related to systemic sclerosis (SSc-PAH)...
  8. ncbi Late-age onset systemic sclerosis
    Rebecca L Manno
    Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
    J Rheumatol 38:1317-25. 2011
    ....
  9. ncbi Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease
    Stephen C Mathai
    Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Arthritis Rheum 60:569-77. 2009
    ..This study was undertaken to characterize determinants of survival among SSc patients with either type of PH who received PAH-specific therapy...
  10. ncbi Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies
    Jerome Le Pavec
    Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Arthritis Rheum 63:2456-64. 2011
    ..This study was undertaken to evaluate our experience with PH-ILD with regard to the efficacy and safety of PAH therapies in this patient cohort...
  11. ncbi Telangiectases in scleroderma: a potential clinical marker of pulmonary arterial hypertension
    Ami A Shah
    Division of Rheumatology, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Mason F Lord Building Center Tower, Suite 4100, Baltimore, MD 21224, USA
    J Rheumatol 37:98-104. 2010
    ..We investigated whether increased numbers of telangiectases in scleroderma associate with measures of pulmonary vascular disease...
  12. ncbi Distinct recognition of antibodies to centromere proteins in primary Sjogren's syndrome compared with limited scleroderma
    A C Gelber
    Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Mason F Lord Building Center Tower, Suite 4100, Room 407, Baltimore MD 21224, USA
    Ann Rheum Dis 65:1028-32. 2006
    ..It is not known whether distinct centromere proteins (CENP) are targeted in primary Sjögren's syndrome (pSS) and scleroderma...
  13. ncbi Cardiac complications of systemic sclerosis: recent progress in diagnosis
    Adel Boueiz
    Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21224, USA
    Curr Opin Rheumatol 22:696-703. 2010
    ..This article reviews the current information about cardiac dysfunction in scleroderma, with special emphasis on its detection and prognostic implications...
  14. ncbi Identification of candidate genes in scleroderma-related pulmonary arterial hypertension
    Dmitry N Grigoryev
    Division of Allergy and Clinical Immunology, Johns Hopkins University, Baltimore, MD 21224, USA
    Transl Res 151:197-207. 2008
    ..Deciphering the role of genes involved in vascular remodeling and PAH development may reveal new treatment targets for this devastating disorder...
  15. ncbi Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis
    Elizabeth N Le
    Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Ann Rheum Dis 70:1104-7. 2011
    ..Immunosuppressive therapy may potentially alter the natural disease course of scleroderma. There have been reports of using mycophenolate mofetil (MMF) for the treatment of scleroderma skin disease...
  16. ncbi Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension
    S C Mathai
    Division of Pulmonary and Critical Care Medicine, Dept of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Eur Respir J 35:95-104. 2010
    ..Future studies to define pertinent mechanisms are warranted...
  17. ncbi Scleroderma-like fibrosing disorders
    Francesco Boin
    Division of Rheumatology, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Mason F Lord Building, Center Tower, Suite 4100, Room 405, Baltimore, MD 21224, USA
    Rheum Dis Clin North Am 34:199-220; ix. 2008
    ..Rheumatologists must be able to promptly recognize them to provide valuable prognostic information and appropriate treatment options for affected patients...
  18. ncbi Scleromyxedema: a case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG)
    Marissa Blum
    Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
    Medicine (Baltimore) 87:10-20. 2008
    ..We discuss the potential therapeutic benefit of IVIG in this condition, where the pathophysiology of the disease is poorly understood, and underscore new data on the potential mechanism of action of IVIG therapy...
  19. ncbi Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma
    Laura K Hummers
    Division of Rheumatology, Johns Hopkins University, Baltimore, MD 21205, USA
    Rheum Dis Clin North Am 29:293-313. 2003
    ..Critical ischemia can cause deep tissue injury and digital loss. An aggressive approach to reversing an ischemic crisis is essential for preventing these severe events...
  20. ncbi Regulation of pulmonary inflammation and fibrosis through expression of integrins alphaVbeta3 and alphaVbeta5 on pulmonary T lymphocytes
    Irina G Luzina
    University of Maryland School of Medicine, Department of Medicine, Baltimore, Maryland 21201, USA
    Arthritis Rheum 60:1530-9. 2009
    ..The aim of this study was to investigate whether pulmonary T cells express profibrotic integrins and regulate collagen accumulation...
  21. ncbi A case-control study of the pathology of oesophageal disease in systemic sclerosis (scleroderma)
    C G P Roberts
    Division of Rheumatology, Johns Hopkins Medical Institutions, 5200 Eastern Avenue, Mason F Lord Building, Center Tower, Suite 4100, Baltimore, MD 21224, USA
    Gut 55:1697-703. 2006
    ..The loss of circular and longitudinal smooth muscle in the distal scleroderma oesophagus may represent loss of normal neural function followed by secondary tissue atrophy, or may be a primary smooth muscle lesion...
  22. ncbi Development of a provisional core set of response measures for clinical trials of systemic sclerosis
    D Khanna
    Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, California 90095, USA
    Ann Rheum Dis 67:703-9. 2008
    ..To develop a provisional core set of response measures for clinical trials of systemic sclerosis (SSc)...
  23. ncbi Increased microchimeric CD4+ T lymphocytes in peripheral blood from women with systemic sclerosis
    Carol M Artlett
    Department of Medicine, Division of Rheumatology, Thomas Jefferson University, Room 509, Bluemle Lifesciences Building, 233 South 10th Street, Philadelphia, Pennsylvania 19107 5541, USA
    Clin Immunol 103:303-8. 2002
    ..These results support the hypothesis that microchimeric CD4+ T cells may be involved in the pathogenesis of SSc...
  24. ncbi Abnormal exhaled ethane concentrations in scleroderma
    K A Cope
    Department of Environmental Health Sciences, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 20705, USA
    Biomarkers 11:70-84. 2006
    ..8, p=0.026, CI=-5.2 to -0.35). These data support the presence of increased oxidative stress among patients with scleroderma that is detected by measuring breath ethane concentrations...
  25. ncbi Antiangiogenic plasma activity in patients with systemic sclerosis
    Mary Jo Mulligan-Kehoe
    Angiogenesis Research Center, Dartmouth Medical School, Lebanon, New Hampshire 03756, USA
    Arthritis Rheum 56:3448-58. 2007
    ..The aim of this study was to investigate the presence of antiangiogenic factors in patients with SSc...
  26. ncbi Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease
    Gordon K Lam
    J Rheumatol 34:1636-7. 2007

Research Grants2

  1. Biomarkers of Vascular Disease in Scleroderma
    Laura Hummers; Fiscal Year: 2007
    ..abstract_text> ..